Literature DB >> 19885950

A study of the comparative effects of hawthorn fruit compound and simvastatin on lowering blood lipid levels.

Hong Xu1, Hou-En Xu, Damien Ryan.   

Abstract

This project studied the lowering blood lipids effect in atherosclerotic ApoE-deficient mice. Group A mice (n = 6), fed with a normal diet, served as the negative control. The experimental groups used mice fed with a high cholesterol diet (HCD) for eight weeks, and then selected for inclusion in the study on the basis of high blood lipid levels and the formation of atherosclerotic lesion plaque, which was indicated by an ultrasound biomicroscopy test. Eighteen mice met the selection criteria (atherosclerotic mice with high blood lipid levels) and these were randomly assigned into three groups B, C and D (n = 6). Group B fed with a HCD, served as the positive control. The intervention Group C was fed with HCD and Simvastatin. The intervention Group D was fed with a HCD and Hawthorn fruit compound (HFC includes Hawthorn and Kiwi fruit extract) for eight weeks. The results showed that after feeding on a HCD, Group B had significantly higher blood lipid levels compared to Group A and this confirmed the validity of Group A and Group B controls in this study. The results also showed that compared to Group B, in both Group C and D, there was a significant reduction in triglyceride and in the ratio between low-density lipoprotein cholesterol (LDL-C) and serum cholesterol. Moreover a reduction of LDL-C was evident in Group D, whereas a similar effect did not occur in Group C. The results indicate that HFC can be considered for the treatment of hyperlipidemia and prevention of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19885950     DOI: 10.1142/S0192415X09007302

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN: 0192-415X            Impact factor:   4.667


  8 in total

1.  Antiobesity and vasoprotective effects of resveratrol in apoE-deficient mice.

Authors:  Seon-Min Jeon; Seung-A Lee; Myung-Sook Choi
Journal:  J Med Food       Date:  2014-01-16       Impact factor: 2.786

2.  The evaluation of chinese therapeutic food for the treatment of moderate dyslipidemia.

Authors:  Shu Sun; Hong Xu; Lawrence Ngeh
Journal:  Evid Based Complement Alternat Med       Date:  2012-03-14       Impact factor: 2.629

3.  Simvastatin reduces atherogenesis and promotes the expression of hepatic genes associated with reverse cholesterol transport in apoE-knockout mice fed high-fat diet.

Authors:  Guohua Song; Jia Liu; Zhenmei Zhao; Yang Yu; Hua Tian; Shutong Yao; Guoli Li; Shucun Qin
Journal:  Lipids Health Dis       Date:  2011-01-18       Impact factor: 3.876

Review 4.  Effect of crataegus usage in cardiovascular disease prevention: an evidence-based approach.

Authors:  Jie Wang; Xingjiang Xiong; Bo Feng
Journal:  Evid Based Complement Alternat Med       Date:  2013-12-29       Impact factor: 2.629

Review 5.  Fruits for Prevention and Treatment of Cardiovascular Diseases.

Authors:  Cai-Ning Zhao; Xiao Meng; Ya Li; Sha Li; Qing Liu; Guo-Yi Tang; Hua-Bin Li
Journal:  Nutrients       Date:  2017-06-13       Impact factor: 5.717

Review 6.  An Overview on Indications and Chemical Composition of Aromatic Waters (Hydrosols) as Functional Beverages in Persian Nutrition Culture and Folk Medicine for Hyperlipidemia and Cardiovascular Conditions.

Authors:  Azadeh Hamedi; Seyed Mahmoud Moheimani; Amirhossein Sakhteman; Hamed Etemadfard; Mahmoodreza Moein
Journal:  J Evid Based Complementary Altern Med       Date:  2017-02-09

Review 7.  Botanical, Phytochemical, Anti-Microbial and Pharmaceutical Characteristics of Hawthorn (Crataegusmonogyna Jacq.), Rosaceae.

Authors:  Federico Martinelli; Anna Perrone; Sanaz Yousefi; Alessio Papini; Stefano Castiglione; Francesco Guarino; Angela Cicatelli; Mitra Aelaei; Neda Arad; Mansour Gholami; Seyed Alireza Salami
Journal:  Molecules       Date:  2021-11-30       Impact factor: 4.411

8.  Evaluation of a crataegus-based multiherb formula for dyslipidemia: a randomized, double-blind, placebo-controlled clinical trial.

Authors:  Miao Hu; Weiwei Zeng; Brian Tomlinson
Journal:  Evid Based Complement Alternat Med       Date:  2014-04-16       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.